FORT LAUDERDALE, Fla. and MONTVALE, N.J., Feb. 25, 2008 (PRIME NEWSWIRE) -- Ivivi Technologies, Inc. (Nasdaq:IVVI) today announced that Andre' DiMino, Vice Chairman and Co-CEO, is scheduled to present a corporate overview at the Growth & Value Investor Conference to be held on February 27th and 28th of 2008 at The Westin Fort Lauderdale in Fort Lauderdale, Florida.
Ivivi Technologies' presentation is scheduled for February 27th at both 7:00 p.m. and 8:20 p.m. Eastern Time with a question and answer session to follow each presentation. The slide presentation discussed at the conference will be available on the Investor Relations section of the Company's website, www.ivivitechnologies.com, under Events and Presentations. The slides will be available for 90 days.
About the Growth & Value Investor Conference
The Growth & Value Investor Conference, "Spring Break for Wall Street," has carefully designated upwards of 30 outstanding publicly traded companies and offers a live, inside look into the core of their strategies, strength of management and the potential for profit. All are welcome. Attendance is free. A Complimentary Cocktail Reception will be held from 4:00 p.m. - 5:00 p.m., and the corporate presentations will follow from 5:00 p.m. - 9:00 p.m. The Growth & Value Investor Conference is presented by LDV Capital Management. For additional information, one-on-one meeting requests or media inquiries, please call James DePelisi, President, LDV Capital Management at 954-746-3117 or email Ldvtrade@aol.com. The conference website is located at: www.LDVCapitalManagement.com.
About Ivivi Technologies, Inc.
Based in Montvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi's research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, modulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company's Electroceuticals(tm) have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders.
Forward-Looking Statements
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including those related to strategic partnerships and future revenues. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company's limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company's products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company's intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company's products and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Form 10-KSB for the fiscal year ended March 31, 2007. The Company assumes no obligation to update the information contained in this press release.